Back to Results
First PageMeta Content
Oxaliplatin / Cisplatin / Chemistry / Alkylating antineoplastic agents / Ammine complexes


A phase I, pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin K. Sankhala1, A. Mita1, R. Adinin2, L. Wood1, M. Beeram1, S. Bullock² N. Yamagata3, K. Matsuno3, T. Fujisawa3, A. T. Phan2 Inst
Add to Reading List

Document Date: 2010-01-29 03:47:14

Open Document

File Size: 242,91 KB

Share Result on Facebook

City

Tokyo / Houston / /

Company

Mebiopharm Co. / /

Country

Japan / /

Event

FDA Phase / /

Facility

University of Texas M. D. Anderson Cancer Center / A. T. Phan2 Institute / University of Texas Health Science Center / /

IndustryTerm

Cancer Therapy / /

MedicalCondition

Non-hematological Adverse events Nausea / tumor / colon carcinoma / gastric carcinoma / cancer / disease / human xenograft tumor / common tumor / metastatic solid tumors / skin cancer / human cancer / nausea / thrombocytopenia / peripheral neuropathy / Vomiting / Fatigue / metastatic solid tumor / archived tumor / allergic reactions / stable disease / Constipation / metastases / anemia / Hypercholesterolemia / breast carcinoma / hematologic malignancy / /

MedicalTreatment

investigational therapy / chemotherapy / radiotherapy / intravenous infusion / immunotherapy / /

Organization

University of Texas M. D. Anderson Cancer Center / Department of Gastrointestinal Medical Oncology / Drug Development / Cancer Therapy and Research Center / A. T. Phan2 Institute for Drug Development / University of Texas Health Science Center at San Antonio / /

/

Position

Major / /

Product

CL / cisplatin / mitomycin / MBP-426 / /

ProvinceOrState

Texas / /

Technology

Pharmacokinetics / Radiation / chemotherapy / treating cancer / transplantation / Drug Development / /

SocialTag